Cost-Effectiveness of Alemtuzumab In The Treatment of Relapsing Forms of Multiple Sclerosis In The United States and Societal Spillover Effects

Abstract

received DMT. Patients with DMT were less likely to have a corticosteroid claim than patients not receiving DMT (39% vs 62%), and less likely to have an ER visit (39% vs 54%) or hospitalization episode (18% vs 29%).

Health Economic Impact of Software-Assisted Brain MRI on Therapeutic Decision-Making and Outcomes of Relapsing-Remitting Multiple Sclerosis Patients—A Microsimulation Study

“…The introduction of DMTs in the early nineties improved the lives of people with MS with about 0.5 QALYs accumulated in 15 years [ 13 ]. Our simulations (see Table 4 ) demonstrate that the introduction of a software-supported treatment paradigm (NEDA-4 with software) has the potential to add 0.34 QALYs compared to a visual analysis of brain MRI scans in 15 years, representing a relative improvement of 68% compared to the introduction of disease-modifying therapies.…”

“…We construct a decision-analytic model as a Markov model in which the states and state transitions are based on disability progression as measured with the EDSS, similar to previous widely used model structures of disability progression in RRMS [ 12 , 13 , 14 ]. In addition to these classical EDSS-based Markov models, the simulated patients can experience both clinical and subclinical disease activity, in the form of EDSS progression, relapses, new lesions, and/or brain atrophy; see Figure 1 .…”

“…Based on these (dis)utility values, the annual QALYs averaged over the considered 10-years horizon can be computed for each strategy. As a 14.67-years horizon was used in [ 13 ] to evaluate the effect of DMTs, the QALY and cost analysis was also performed for 15 years.…”